JAZZ vs SPRB
JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments. SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | JAZZ | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $255.43 | $41.99 | |
| Market cap as of 2026-07-29 | $16.4B | $116M | |
| P/E as of 2026-07-29 | 555.02 | n/a | |
| PEG as of 2026-07-29 | 58.02 | n/a | |
| Net margin as of 2026-07-29 | +0.7% | -1079.9% | JAZZ higher |
| Gross margin as of 2026-07-29 | +88.0% | n/a | |
| Operating margin as of 2026-07-29 | -0.8% | -1143.4% | JAZZ higher |
| ROE as of 2026-07-29 | +0.7% | -155.4% | JAZZ higher |
| ROA as of 2026-07-29 | +0.3% | -101.7% | JAZZ higher |
| Debt / equity as of 2026-07-29 | 1.18 | 0.19 | SPRB lower |
| Revenue growth (YoY) as of 2026-07-29 | +9.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.3% | n/a | |
| Beta as of 2026-07-29 | 0.37 | 3.48 | |
| 1-year return as of 2026-07-27 close | +116.0% | n/a |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.